Vanguard Group
EPZM

Vanguard Group’s Epizyme, Inc EPZM Stock Holding History

Vanguard Group’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-7,540,469
Closed -$11.1M – 4642
2022
Q2 		$11.1M Buy
7,540,469
+90,313
+1% +$66.4K ﹤0.01% 2943
2022
Q1 		$8.57M Buy
7,450,156
+1,465,248
+24% +$2.39M ﹤0.01% 3236
2021
Q4 		$15M Sell
5,984,908
-1,873,365
-24% -$7.36M ﹤0.01% 2991
2021
Q3 		$40.2M Sell
7,858,273
-43,036
-0.5% -$261K ﹤0.01% 2483
2021
Q2 		$65.7M Buy
7,901,309
+71,331
+0.9% +$601K ﹤0.01% 2226
2021
Q1 		$68.2M Buy
7,829,978
+264,731
+3% +$2.74M ﹤0.01% 2138
2020
Q4 		$82.2M Buy
7,565,247
+224,117
+3% +$2.76M ﹤0.01% 1932
2020
Q3 		$87.6M Buy
7,341,130
+130,170
+2% +$1.74M ﹤0.01% 1748
2020
Q2 		$116M Buy
7,210,960
+223,768
+3% +$3.91M ﹤0.01% 1595
2020
Q1 		$108M Buy
6,987,192
+180,859
+3% +$3.88M ﹤0.01% 1482
2019
Q4 		$167M Sell
6,806,333
-339,060
-5% -$5.03M 0.01% 1478
2019
Q3 		$73.7M Buy
7,145,393
+66,923
+0.9% +$844K ﹤0.01% 1885
2019
Q2 		$88.8M Buy
7,078,470
+1,630,171
+30% +$21M ﹤0.01% 1814
2019
Q1 		$67.5M Buy
5,448,299
+1,805,195
+50% +$20.2M ﹤0.01% 1941
2018
Q4 		$22.4M Sell
3,643,104
-927,035
-20% -$7.08M ﹤0.01% 2397
2018
Q3 		$48.4M Buy
4,570,139
+84,726
+2% +$967K ﹤0.01% 2159
2018
Q2 		$60.8M Buy
4,485,413
+168,587
+4% +$2.62M ﹤0.01% 2031
2018
Q1 		$76.6M Buy
4,316,826
+71,143
+2% +$1.2M ﹤0.01% 1859
2017
Q4 		$53.3M Buy
4,245,683
+268,253
+7% +$3.9M ﹤0.01% 2035
2017
Q3 		$75.8M Buy
3,977,430
+557,586
+16% +$8.51M ﹤0.01% 1853
2017
Q2 		$51.6M Buy
3,419,844
+200,982
+6% +$3.04M ﹤0.01% 2002
2017
Q1 		$55.2M Buy
3,218,862
+139,066
+5% +$1.85M ﹤0.01% 1962
2016
Q4 		$37.3M Buy
3,079,796
+120,701
+4% +$1.26M ﹤0.01% 2119
2016
Q3 		$29.1M Buy
2,959,095
+132,285
+5% +$1.21M ﹤0.01% 2190
2016
Q2 		$28.9M Buy
2,826,810
+81,472
+3% +$908K ﹤0.01% 2164
2016
Q1 		$33.3M Buy
2,745,338
+1,006,908
+58% +$10.2M ﹤0.01% 2062
2015
Q4 		$27.9M Buy
1,738,430
+43,037
+3% +$638K ﹤0.01% 2155
2015
Q3 		$21.8M Buy
1,695,393
+79,053
+5% +$1.6M ﹤0.01% 2251
2015
Q2 		$38.8M Buy
1,616,340
+220,923
+16% +$4.25M ﹤0.01% 2068
2015
Q1 		$26.2M Buy
1,395,417
+306,927
+28% +$6.34M ﹤0.01% 2210
2014
Q4 		$20.5M Buy
1,088,490
+69,254
+7% +$1.62M ﹤0.01% 2226
2014
Q3 		$27.6M Buy
1,019,236
+307,504
+43% +$9.56M ﹤0.01% 2084
2014
Q2 		$22.1M Buy
711,732
+24,616
+4% +$580K ﹤0.01% 2177
2014
Q1 		$15.6M Buy
687,116
+430,775
+168% +$13.1M ﹤0.01% 2283
2013
Q4 		$5.33M Buy
256,341
+57,840
+29% +$1.68M ﹤0.01% 2768
2013
Q3 		$7.97M Buy
198,501
+189,655
+2,144% +$6.42M ﹤0.01% 2506
2013
Q2 		$249K Buy
+8,846
New +$227K ﹤0.01% 3612

Other funds holding EPZM

Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Vanguard Group's EPZM Position: Q3 2022 in Review

Vanguard Group sold out of Epizyme, Inc (EPZM) in Q3 2022, closing a stake of 7,540,469 shares — an estimated $11.1M sold.

Vanguard Group first reported a position in EPZM in Q2 2013 and held it in 37 quarters. The position peaked at $167M in Q4 2019. 0 funds tracked by Wall St. Rank hold EPZM as of Q3 2022.

  • Vanguard Group reported no remaining Epizyme, Inc position as of Q3 2022 after selling out during the quarter.
  • Vanguard Group sold 7,540,469 Epizyme, Inc shares in Q3 2022, an estimated $11.1M.
  • Vanguard Group first reported a position in Epizyme, Inc in Q2 2013 and held it in 37 quarters.
  • Vanguard Group's Epizyme, Inc position peaked at $167M in Q4 2019.
  • 0 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2022.

Based on Vanguard Group's 13F filing for Q3 2022, filed 14 Nov 2022.